FBIO vs. SGMO, IRWD, ACHV, DOMH, AGEN, CRIS, SABS, BOLT, MTEM, and AMGN
Should you be buying Fortress Biotech stock or one of its competitors? The main competitors of Fortress Biotech include Sangamo Therapeutics (SGMO), Ironwood Pharmaceuticals (IRWD), Achieve Life Sciences (ACHV), Dominari (DOMH), Agenus (AGEN), Curis (CRIS), SAB Biotherapeutics (SABS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), and Amgen (AMGN). These companies are all part of the "biotechnology" industry.
Fortress Biotech vs.
Sangamo Therapeutics (NASDAQ:SGMO) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, community ranking, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.
Sangamo Therapeutics currently has a consensus target price of $4.50, suggesting a potential upside of 810.01%. Fortress Biotech has a consensus target price of $21.00, suggesting a potential upside of 1,113.87%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Fortress Biotech is more favorable than Sangamo Therapeutics.
Sangamo Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500.
In the previous week, Sangamo Therapeutics had 5 more articles in the media than Fortress Biotech. MarketBeat recorded 9 mentions for Sangamo Therapeutics and 4 mentions for Fortress Biotech. Sangamo Therapeutics' average media sentiment score of 0.99 beat Fortress Biotech's score of -0.22 indicating that Sangamo Therapeutics is being referred to more favorably in the media.
Fortress Biotech has lower revenue, but higher earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.
56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by company insiders. Comparatively, 33.4% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Fortress Biotech has a net margin of -84.53% compared to Sangamo Therapeutics' net margin of -257.87%. Fortress Biotech's return on equity of 0.00% beat Sangamo Therapeutics' return on equity.
Sangamo Therapeutics received 129 more outperform votes than Fortress Biotech when rated by MarketBeat users. However, 63.69% of users gave Fortress Biotech an outperform vote while only 62.69% of users gave Sangamo Therapeutics an outperform vote.
Summary
Fortress Biotech beats Sangamo Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Fortress Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fortress Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:FBIO) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy FBIO Stock Free FBIO Stock Alerts